India records 1.15 lakh daily coronavirus cases & 630 deaths;”Boost immunity and stay fit :PM

COVID-19: AstraZeneca vaccine benefits still ‘largely positive’

India records 1.15 lakh daily coronavirus cases & 630 deaths; “Boost immunity and stay fit: PM
April 7, 2021:India today recorded the biggest ever single-day rise of 1,15,736 new COVID-19 cases and 630 deaths, pushing India’s tally of cases to 1,28,01,785, death toll to 1,66,177.

Union Health Ministry,active COVID-19 cases recorded at 8,43,473, while  1,17,92,135 people have recovered from disease so far.

 Concerned over the situation, Prime Minister, on World health day today said: The Government of India is taking numerous measures including Ayushman Bharat and PM Janaushadhi Yojana to ensure people get access to top quality and affordable healthcare. India is also conducting the world’s largest vaccination drive to strengthen the fight against COVID-19.

On World Health Day, let us keep the focus on fighting COVID-19 by taking all possible precautions including wearing a mask, regularly washing hands, and following the other protocols. 

At the same time, do take all possible steps to boost immunity and stay fit.

World Health Day is a day to reaffirm our gratitude and appreciation to all those who work day and night to keep our planet healthy. It’s also a day to reiterate our commitment to supporting research and innovation in healthcare.”


The benefits of the AstraZeneca COVID-19 vaccine are still “largely positive” and outweigh the risk of rare but serious blood clots, according to an official with the World Health Organization (WHO), speaking on Tuesday during the agency’s regular press briefing from Geneva. 

Dr. Rogério  Pinto de Sá Gaspar, Director for Regulation and Prequalification, was responding to a journalist’s question regarding links between the vaccine and cerebral venous sinus thrombosis, a rare blood clotting syndrome. 

The European Medicines Agency (EMA) on Tuesday denied that it had established any link, following reports that one of its experts stated there was a connection.  

Expert meetings underway 

Meanwhile, an EMA committee that monitors the safety of medicines has been meeting to assess the data, which is also being reviewed by a regulatory body in the United Kingdom.  WHO is following both proceedings. 

“What we can say is that the appraisal that we have for the moment, and this is under consideration by the experts, is that the benefit-risk assessment for the vaccine is still largely positive”, said Dr Pinto de Sá Gaspar. 

He reported that “thrombolytic events” are rare, and are now being categorized in terms of their distribution within the population. 

“For the time being, there is no evidence that the benefit-risk assessment for the vaccine needs to be changed”, he added. “And we know from the  data coming from countries like the UK and others, that the benefits are really important in terms of reduction of the mortality of populations that are being vaccinated.” 

WHO’s Global Advisory Committee on Vaccine Safety is due to meet on Wednesday, which also will look at the data, with a conclusion expected later in the week. 

Stigma and virus variants 

WHO continues to work with a group of scientists worldwide to develop nomenclature for variants of the new coronavirus that causes COVID-19

Many people, including health experts, have been referring to the variants by the countries in which they were first detected, something the UN agency wants to change. 

“We need to make sure that any of the names that are used do not further stigmatize a person, or the last name, or a location, inadvertently”, said Dr. Maria Van Kerhove, WHO technical lead on COVID-19, responding to a question from a South African journalist. 

“There should be no stigma associated with these viruses being detected, and unfortunately we still see that happening.”  

Currently, there are three variants: B117, first identified in the UK; B 1.351, which was first identified in South Africa, and P1, a variant first detected in Japan but circulating in Brazil.


Please click the link below & support our initiative


Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker